Inhibikase Therapeutics, Inc. financial data

Symbol
IKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3350 Riverwood Parkway Se, Suite 1900, Atlanta, GA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 362 % -56.3%
Debt-to-equity 38.1 % +165%
Return On Equity -194 % -132%
Return On Assets -141 % -92.2%
Operating Margin -23.9K % -204%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.46M shares +39.6%
Common Stock, Shares, Outstanding 7.22M shares +36.4%
Entity Public Float 19.1M USD +2.14%
Common Stock, Value, Issued 7.22K USD +36.4%
Weighted Average Number of Shares Outstanding, Basic 7.54M shares +44.2%
Weighted Average Number of Shares Outstanding, Diluted 7.54M shares +44.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 79.6K USD -68.4%
Research and Development Expense 12.1M USD -10.2%
Costs and Expenses 19.1M USD -4.66%
Operating Income (Loss) -19M USD +3.85%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -18.4M USD +3.4%
Earnings Per Share, Basic -2.87 USD/shares +43.6%
Earnings Per Share, Diluted -2.87 USD/shares +43.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.17M USD +27.5%
Marketable Securities, Current 4.85M USD -74.5%
Assets, Current 8.6M USD -60.9%
Property, Plant and Equipment, Net 60.2K USD -30.4%
Operating Lease, Right-of-Use Asset 164K USD -40.9%
Assets 8.83M USD -60.5%
Accounts Payable, Current 1.34M USD +77.8%
Accrued Liabilities, Current 2.03M USD +11.1%
Liabilities, Current 3.7M USD +35.5%
Operating Lease, Liability, Noncurrent 25.6K USD -82.9%
Liabilities 3.73M USD +29.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.02K USD +40.3%
Retained Earnings (Accumulated Deficit) -76.5M USD -31.6%
Stockholders' Equity Attributable to Parent 5.1M USD -73.8%
Liabilities and Equity 8.83M USD -60.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.87M USD +35.2%
Net Cash Provided by (Used in) Financing Activities 367K USD -95.7%
Net Cash Provided by (Used in) Investing Activities -3.31M USD +43.3%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 7.22M shares +36.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.09M USD +62%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 18.8M USD +51.5%
Deferred Tax Assets, Gross 18.8M USD +51.5%
Operating Lease, Liability 178K USD -40.3%
Depreciation 26.3K USD -84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.96M USD +16.6%
Lessee, Operating Lease, Liability, to be Paid 191K USD
Property, Plant and Equipment, Gross 104K USD -59.7%
Operating Lease, Liability, Current 152K USD +2.88%
Lessee, Operating Lease, Liability, to be Paid, Year Two 115K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 75.6K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.7K USD -68.7%
Deferred Tax Assets, Operating Loss Carryforwards 9.18M USD +33.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.97K USD
Share-based Payment Arrangement, Expense 336K USD -25.3%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%